Based on the results of the meta-analysis of EGFR, compared with the control group, febuxostat significantly improves the EGFR level in patients with CKD with HUA (SMD: 3.21, 95% Cl: 1.17, 5.25, and P < 0.01). This evidence concerns the gene EGFR and chronic kidney disease.